Developer docs
API playgroundTry for free, no card

Search company profiles

Acera Surgical

Full company profile

uuid0000g8v

Namestring
Acera Surgical
Legal namestring
Acera Surgical, Inc.
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Acera Surgical is a St. Louis-based bioscience company founded in 2013 that develops and commercializes fully synthetic electrospun fiber matrix products for regenerative wound care and soft tissue repair. Its technology platform produces sub-cellular (sub-micron to micron) polymer fibers that are structurally similar to native human extracellular matrix, are free of animal and human components, resist enzymatic degradation, and resorb via hydrolysis at a rate designed to match tissue ingrowth. The product portfolio centers on the Restrata platform (Restrata Sheet, Restrata Meshed, and Restrata MiniMatrix form factors) for wound management and soft tissue reinforcement, alongside Cerafix, a synthetic dural repair matrix for neurosurgical applications. Multiple FDA 510(k) clearances and 38 peer-reviewed clinical publications, including Level I randomized controlled trial evidence, support the products' clinical positioning across surgical specialties including orthopedic trauma, plastic and reconstructive surgery, head and neck, foot and ankle, and wound care.

The company operates a direct field sales go-to-market model, employing Senior Account Executives and Associate Account Executives who engage hospitals, surgical centers, and wound care facilities across multiple US markets. Revenue is generated through one-time hardware sales of FDA-cleared medical devices to healthcare providers, with pricing handled via quote-based B2B contracts rather than public list pricing. Reported clinical outcomes include 96% complete closure rates for acute surgical wounds, 82-89% closure rates for chronic wounds, over 95% average skin graft take rates, and Level I RCT evidence showing 74% complete wound closure in the Restrata group versus 33% in control for diabetic foot ulcers. Following a strategic sale process, Acera was acquired by Solventum Corporation (NYSE: SOLV, spun off from 3M in April 2024) for $725 million in cash plus up to $125 million in contingent milestone payments, with the transaction announced November 2025 and completed December 2025; Acera now operates as a wholly-owned subsidiary of Solventum.

Short descriptiontext

Acera Surgical is a St. Louis-based bioscience company developing fully synthetic electrospun fiber matrix products (Restrata and Cerafix) for regenerative wound care, soft tissue reinforcement, and dural repair, sold directly to hospitals and surgical centers.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
101–250
akta.pro rankint
HeadquartersSt Louis, United States
HQ citystring
St Louis
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
electrospun fiber matrix, regenerative wound care, soft tissue repair, synthetic surgical materials, dural repair devices
Industry3 codes
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAD
Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)
NAICS code2 codes
  • Surgical Appliance and Supplies Manufacturing339113
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Orthopedic, Prosthetic & Surgical Appliances & Supplies3842
  • Surgical & Medical Instruments & Apparatus3841
Product category
Regenerative Wound Care Medical Devices
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Medical Device Sales
TypeHardware Sales
Description

Acera Surgical generates revenue through the sale of its FDA-cleared medical devices including Restrata (Sheet, Meshed, MiniMatrix) and Cerafix. These are one-time use products sold to hospitals and surgical centers for soft tissue repair and wound management procedures.

in.investing.com
Marketing channels8 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 3 records shown
1Restrata
Description

First electrospun fiber matrix for soft tissue repair, including Restrata Sheet, Restrata Meshed, and Restrata MiniMatrix products for wound management and soft tissue reinforcement.

acera-surgical.com
+2 more records
Core offering1 text field

Acera Surgical designs, manufactures, and sells fully synthetic, electrospun fiber matrix medical devices sold under the Restrata and Cerafix brands. These FDA 510(k)-cleared products are used by surgeons and wound care specialists for management of chronic and acute wounds, treatment of dermal scarring, and surgical soft tissue reinforcement including tendon, peripheral nerve, and dural repair.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • 96% complete closure rate for acute surgical wounds (average 3.8 weeks to closure)
+5 more records
Product overview1 text field

Acera Surgical is a bioscience company developing and commercializing fully engineered electrospun fiber matrix products for regenerative medicine. The company's core product portfolio centers on the Restrata platform, which includes three distinct form factors: Restrata Sheet (standard electrospun matrix), Restrata Meshed (pre-meshed expandable version), and Restrata MiniMatrix (micronized dispersible form). All Restrata products are fully synthetic, resorbable matrices engineered to be structurally similar to human extracellular matrix (ECM) and are indicated for wound management and soft tissue reinforcement. The company also offers Cerafix, a separate product line for dural repair in neurosurgical applications. Acera's technology is based on patented electrospinning processes that create sub-cellular fibers free of animal and human components.

Product and service4 records
1Restrata Sheet
CategoryWound care & soft tissue repair medical device
Description

Restrata Sheet is a fully synthetic electrospun fiber matrix offered as a sheet form, FDA 510(k)-cleared for management of chronic and acute wounds (including partial and full-thickness wounds), treatment of dermal scarring, and surgical soft tissue reinforcement. It is intended for use by surgeons and wound care specialists across multiple surgical specialties.

2Restrata Meshed
CategoryWound care & soft tissue repair medical device
Description

Restrata Meshed is a meshed (fenestrated) form variant of the Restrata electrospun fiber matrix, providing the same FDA 510(k)-cleared indications for wound management and soft tissue reinforcement while allowing exudate drainage and improved conformability to irregular wound surfaces.

3Restrata MiniMatrix
CategoryWound care & soft tissue repair medical device
Description

Restrata MiniMatrix is a small-format electrospun fiber matrix in the Restrata product family, designed for surgical applications requiring a compact matrix such as peripheral nerve and tendon repair, while sharing the same FDA 510(k)-cleared synthetic scaffold technology as the broader Restrata line.

4Cerafix Dural Repair Matrix
CategoryNeurosurgical dural repair medical device
Description

Cerafix is Acera Surgical's FDA 510(k)-cleared electrospun fiber matrix specifically indicated for use as a dura mater substitute in the repair of the dura mater following neurosurgical procedures. It leverages the same synthetic, enzymatic degradation-resistant electrospun platform as Restrata.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Medtronic is a major player in neurosurgery and sells dural repair grafts (e.g., Durepair) and other neurosurgical implants that compete with Acera's Cerafix. Its scale, surgeon relationships, and capital position make it the dominant incumbent in Cerafix's category.

TypeBroad incumbent
Description

Coloplast's Wound & Skin Care business sells Biatain, Flaminal, and other advanced wound care dressings into hospitals and home care, overlapping with Acera's wound care call points. Coloplast provides a relevant scale benchmark for commercial reach and reimbursement infrastructure.

TypeDirect peer
Description

Organogenesis is a direct competitor in advanced wound care with Apligraf, Dermagraft, and PuraPly, selling into the same hospital wound care and surgical specialty call points Acera targets. Both companies compete on clinical evidence and reimbursement coverage in chronic wound healing.

TypeBroad incumbent
Description

BD's Medical Surgery segment sells biosurgery and soft tissue repair products (e.g., Avitene, Surgiflo) into the same surgical specialty call points Acera targets. As a broad incumbent, BD exemplifies the strategic-acquirer archetype that valued Acera's differentiated synthetic platform.

TypeBroad incumbent
Description

ConvaTec offers Aquacel and other advanced wound care and skin protection products targeting the same hospitals, wound care clinics, and podiatric call points as Acera. Its broad portfolio and distribution muscle make it a key competitor for formulary placement.

TypeBroad incumbent
Description

Stryker's Medical/Surgical and Orthopedics & Spine segments overlap with Acera's orthopedic trauma and soft tissue reinforcement use cases. As a diversified medtech incumbent, Stryker represents both a competitor for hospital budgets and a potential acquirer benchmark.

TypeBroad incumbent
Description

Baxter's Advanced Surgery business (surgical sealants, haemostats, soft tissue repair products such as Tisseel and Floseal) competes with Restrata in surgical soft tissue reinforcement. Baxter's global hospital salesforce provides a useful comparator for international expansion economics.

TypeBroad incumbent
Description

Smith+Nephew's Advanced Wound Management portfolio (e.g., PICO, ALLEVYN, collagen matrices) competes with Restrata in hospital and outpatient wound care. As a much larger diversified medtech player, it sets pricing and formulary benchmarks Acera must match or differentiate against.

TypeDirect peer
Description

MiMedx markets placental tissue allografts (e.g., EpiFix, AmnioFix) for wound care and surgical recovery, overlapping directly with Restrata in chronic wounds and soft tissue repair. MiMedx competes on biological vs synthetic positioning and is sold via the same surgeon-channel dynamics.

TypeDirect peer
Description

Integra competes directly with Acera across neurosurgical dural repair (DuraGen, DuraSeal) and regenerative wound care/soft tissue repair (Integra Dermal Regeneration Template). Like Acera, Integra sells through a hospital-focused sales force and relies on specialty surgical adoption, making it the closest like-for-like comparable.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance3 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Acera Surgical

Regenerative Wound Care Medical Devicesacera-surgical.com

Acera Surgical is a St. Louis-based bioscience company developing fully synthetic electrospun fiber matrix products (Restrata and Cerafix) for regenerative wound care, soft tissue reinforcement, and dural repair, sold directly to hospitals and surgical centers.

What Acera Surgical does

Acera Surgical is a St. Louis-based bioscience company founded in 2013 that develops and commercializes fully synthetic electrospun fiber matrix products for regenerative wound care and soft tissue repair. Its technology platform produces sub-cellular (sub-micron to micron) polymer fibers that are structurally similar to native human extracellular matrix, are free of animal and human components, resist enzymatic degradation, and resorb via hydrolysis at a rate designed to match tissue ingrowth. The product portfolio centers on the Restrata platform (Restrata Sheet, Restrata Meshed, and Restrata MiniMatrix form factors) for wound management and soft tissue reinforcement, alongside Cerafix, a synthetic dural repair matrix for neurosurgical applications. Multiple FDA 510(k) clearances and 38 peer-reviewed clinical publications, including Level I randomized controlled trial evidence, support the products' clinical positioning across surgical specialties including orthopedic trauma, plastic and reconstructive surgery, head and neck, foot and ankle, and wound care.

The company operates a direct field sales go-to-market model, employing Senior Account Executives and Associate Account Executives who engage hospitals, surgical centers, and wound care facilities across multiple US markets. Revenue is generated through one-time hardware sales of FDA-cleared medical devices to healthcare providers, with pricing handled via quote-based B2B contracts rather than public list pricing. Reported clinical outcomes include 96% complete closure rates for acute surgical wounds, 82-89% closure rates for chronic wounds, over 95% average skin graft take rates, and Level I RCT evidence showing 74% complete wound closure in the Restrata group versus 33% in control for diabetic foot ulcers. Following a strategic sale process, Acera was acquired by Solventum Corporation (NYSE: SOLV, spun off from 3M in April 2024) for $725 million in cash plus up to $125 million in contingent milestone payments, with the transaction announced November 2025 and completed December 2025; Acera now operates as a wholly-owned subsidiary of Solventum.

Acera Surgical firmographics

Firmographics
Name
Acera Surgical
Legal name
Acera Surgical, Inc.
Website
https://acera-surgical.com
Company type
Private
Founded year
2013
Operating status
Acquired
Headcount range
101–250 employees
Short description
Acera Surgical is a St. Louis-based bioscience company developing fully synthetic electrospun fiber matrix products (Restrata and Cerafix) for regenerative wound care, soft tissue reinforcement, and dural repair, sold directly to hospitals and surgical centers.
Ownership category
akta.pro rank

Acera Surgical industry classification

Industry
Product category
Regenerative Wound Care Medical Devices
NAICS
Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112)
SIC
Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842), Surgical & Medical Instruments & Apparatus (3841)
akta.pro industry
PRIMARYHLAHALAE
Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Wound Care, Ostomy & Continence Products
SECONDARYHLAAAGAB
Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials)
Healthcare & Life Sciences/Biotechnology & Biologics/Regenerative Medicine & Tissue Engineering
SECONDARYHLAHAEAD
Neurosurgical Implants & Cranial/CMF (Cranial Plates, Dural Repair, Shunts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Implants & Prosthetics (Orthopedic/Neuro/Spine/Dental)

Keywords

  • Electrospun fiber matrix
  • Regenerative wound care
  • Soft tissue repair
  • Synthetic surgical materials
  • Dural repair devices

Where Acera Surgical is headquartered

Location

Headquarters

HQ city
St Louis
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Acera Surgical business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations, Infrastructure

Revenue model

  1. Medical Device Sales: Acera Surgical generates revenue through the sale of its FDA-cleared medical devices including Restrata (Sheet, Meshed, MiniMatrix) and Cerafix. These are one-time use products sold to hospitals and surgical centers for soft tissue repair and wound management procedures.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels8 records

Acera Surgical product offering

Product offering

Core offering

Acera Surgical designs, manufactures, and sells fully synthetic, electrospun fiber matrix medical devices sold under the Restrata and Cerafix brands. These FDA 510(k)-cleared products are used by surgeons and wound care specialists for management of chronic and acute wounds, treatment of dermal scarring, and surgical soft tissue reinforcement including tendon, peripheral nerve, and dural repair.

Product overview

Acera Surgical is a bioscience company developing and commercializing fully engineered electrospun fiber matrix products for regenerative medicine. The company's core product portfolio centers on the Restrata platform, which includes three distinct form factors: Restrata Sheet (standard electrospun matrix), Restrata Meshed (pre-meshed expandable version), and Restrata MiniMatrix (micronized dispersible form). All Restrata products are fully synthetic, resorbable matrices engineered to be structurally similar to human extracellular matrix (ECM) and are indicated for wound management and soft tissue reinforcement. The company also offers Cerafix, a separate product line for dural repair in neurosurgical applications. Acera's technology is based on patented electrospinning processes that create sub-cellular fibers free of animal and human components.

Differentiator

Problem solved

Functional benefit

Brands

  • Restrata: First electrospun fiber matrix for soft tissue repair, including Restrata Sheet, Restrata Meshed, and Restrata MiniMatrix products for wound management and soft tissue reinforcement.
  • Cerafix
  • Covora

Products and services

  • Restrata Sheet Restrata Sheet is a fully synthetic electrospun fiber matrix offered as a sheet form, FDA 510(k)-cleared for management of chronic and acute wounds (including partial and full-thickness wounds), treatment of dermal scarring, and surgical soft tissue reinforcement. It is intended for use by surgeons and wound care specialists across multiple surgical specialties.
  • Restrata Meshed Restrata Meshed is a meshed (fenestrated) form variant of the Restrata electrospun fiber matrix, providing the same FDA 510(k)-cleared indications for wound management and soft tissue reinforcement while allowing exudate drainage and improved conformability to irregular wound surfaces.
  • Restrata MiniMatrix Restrata MiniMatrix is a small-format electrospun fiber matrix in the Restrata product family, designed for surgical applications requiring a compact matrix such as peripheral nerve and tendon repair, while sharing the same FDA 510(k)-cleared synthetic scaffold technology as the broader Restrata line.
  • Cerafix Dural Repair Matrix Cerafix is Acera Surgical's FDA 510(k)-cleared electrospun fiber matrix specifically indicated for use as a dura mater substitute in the repair of the dura mater following neurosurgical procedures. It leverages the same synthetic, enzymatic degradation-resistant electrospun platform as Restrata.

Quantifiable outcome

  • 96% complete closure rate for acute surgical wounds (average 3.8 weeks to closure)
  • +5 more outcomes

Companies that use Acera Surgical

Customer profile

Named customers5 records

Segments3 records

Ideal customer profiles1 record

Acera Surgical technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Acera Surgical partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Acera Surgical competitors and assessment

Company assessment

Broad incumbents

  • Medtronic: Medtronic is a major player in neurosurgery and sells dural repair grafts (e.g., Durepair) and other neurosurgical implants that compete with Acera's Cerafix. Its scale, surgeon relationships, and capital position make it the dominant incumbent in Cerafix's category.
  • Coloplast: Coloplast's Wound & Skin Care business sells Biatain, Flaminal, and other advanced wound care dressings into hospitals and home care, overlapping with Acera's wound care call points. Coloplast provides a relevant scale benchmark for commercial reach and reimbursement infrastructure.
  • Becton, Dickinson and Company (BD): BD's Medical Surgery segment sells biosurgery and soft tissue repair products (e.g., Avitene, Surgiflo) into the same surgical specialty call points Acera targets. As a broad incumbent, BD exemplifies the strategic-acquirer archetype that valued Acera's differentiated synthetic platform.
  • ConvaTec: ConvaTec offers Aquacel and other advanced wound care and skin protection products targeting the same hospitals, wound care clinics, and podiatric call points as Acera. Its broad portfolio and distribution muscle make it a key competitor for formulary placement.
  • Stryker: Stryker's Medical/Surgical and Orthopedics & Spine segments overlap with Acera's orthopedic trauma and soft tissue reinforcement use cases. As a diversified medtech incumbent, Stryker represents both a competitor for hospital budgets and a potential acquirer benchmark.
  • Baxter International: Baxter's Advanced Surgery business (surgical sealants, haemostats, soft tissue repair products such as Tisseel and Floseal) competes with Restrata in surgical soft tissue reinforcement. Baxter's global hospital salesforce provides a useful comparator for international expansion economics.
  • Smith+Nephew: Smith+Nephew's Advanced Wound Management portfolio (e.g., PICO, ALLEVYN, collagen matrices) competes with Restrata in hospital and outpatient wound care. As a much larger diversified medtech player, it sets pricing and formulary benchmarks Acera must match or differentiate against.

Direct peers

  • Organogenesis: Organogenesis is a direct competitor in advanced wound care with Apligraf, Dermagraft, and PuraPly, selling into the same hospital wound care and surgical specialty call points Acera targets. Both companies compete on clinical evidence and reimbursement coverage in chronic wound healing.
  • MiMedx: MiMedx markets placental tissue allografts (e.g., EpiFix, AmnioFix) for wound care and surgical recovery, overlapping directly with Restrata in chronic wounds and soft tissue repair. MiMedx competes on biological vs synthetic positioning and is sold via the same surgeon-channel dynamics.
  • Integra LifeSciences: Integra competes directly with Acera across neurosurgical dural repair (DuraGen, DuraSeal) and regenerative wound care/soft tissue repair (Integra Dermal Regeneration Template). Like Acera, Integra sells through a hospital-focused sales force and relies on specialty surgical adoption, making it the closest like-for-like comparable.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

Acera Surgical compliance and trust

Trust signal

Compliance3 records

Acera Surgical financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Acera Surgical leadership team

Management profile

Number of profiles

Profiles2 records

Acera Surgical funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Acera Surgical M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Acera Surgical

What does Acera Surgical do?

Acera Surgical designs, manufactures, and sells fully synthetic, electrospun fiber matrix medical devices sold under the Restrata and Cerafix brands. These FDA 510(k)-cleared products are used by surgeons and wound care specialists for management of chronic and acute wounds, treatment of dermal scarring, and surgical soft tissue reinforcement including tendon, peripheral nerve, and dural repair.

Is Acera Surgical a public or private company?

Acera Surgical is a private company. It is classified as corporate owned and is currently acquired.

When was Acera Surgical founded?

Acera Surgical was founded in 2013. It employs 101 to 250 people.

Where is Acera Surgical based?

Acera Surgical is headquartered in St Louis, United States, in the North America region.

How does Acera Surgical make money?

One revenue line is on record: medical Device Sales.

Who are Acera Surgical's main competitors?

Broad incumbents on record are Medtronic, Coloplast, Becton, Dickinson and Company (BD), ConvaTec, Stryker, Baxter International and Smith+Nephew. Direct peers are Organogenesis, MiMedx and Integra LifeSciences.

Does Acera Surgical have an API?

No public API is recorded for Acera Surgical.

What industry is Acera Surgical in?

Acera Surgical's product category is Regenerative Wound Care Medical Devices. Its primary akta.pro industry code is HLAHALAE, Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts), with a secondary code of HLAAAGAB, Tissue-Engineered Constructs & Scaffolds (natural/synthetic biomaterials). Its NAICS code is 339113 and its SIC code is 3842.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireActive Wound Care Market worth $4.50 billion by 2031 - Exclusive Report by MarketsandMarkets™The active wound care market is projected to grow from $3.19 billion in 2026 to $4.50 billion by 2031, a 7.1% CAGR. North America held the largest regional share at 44.9% in 2025, and biological skin substitutes led product type with 56.8% share. Growth is driven by chronic wound prevalence and reimbursement changes, with M&A activity focusing on regenerative technologies.TradingViewSOLV Q2 Deep Dive: Portfolio Restructuring and ERP Transition Shape OutlookSolventum reported Q2 CY2026 revenue of $2.21 billion and adjusted EPS of $2.55, beating analyst estimates despite a negative market reaction driven by temporary ERP-related order timing and ongoing portfolio restructuring. The company raised its full-year adjusted EPS guidance to $7.15 and announced plans to separate its Health Information Systems (HIS) business to focus on MedTech, while acknowledging the acquisition of Acera contributed significant growth.EIN PresswireSoft Tissue Repair Market Growing at 5.3% CAGR Through 2033: Persistence Market ResearchThe global soft tissue repair market is projected to grow from USD 15.9 billion in 2026 to USD 22.9 billion by 2033, representing a 5.3% CAGR, driven by increasing surgical procedures and advancements in minimally invasive techniques. North America leads the market with a 35.2% share, while the Asia-Pacific region is expected to record the fastest growth at 6.6% CAGR. Key developments shaping the market include Solventum's acquisition of Acera Surgical in November 2025 and Vericel Corporation's FDA approval for MACI in August 2024.BioSpaceSolventum Completes Acquisition of Acera SurgicalSolventum completed the acquisition of Acera Surgical, a bioscience company focused on regenerative wound care, for $725 million with additional contingent payments. The deal aims to expand Solventum's med-surg portfolio with Acera's synthetic tissue matrix technology, expected to be slightly dilutive to 2026 EPS and accretive from 2027 onward. The acquisition supports Solventum's strategic transformation plan and growth in the wound care market.Investing.comSolventum completes acquisition of Acera Surgical for $725 million By Investing.comSolventum (NYSE:SOLV) has completed its acquisition of privately held bioscience company Acera Surgical for an upfront cash payment of $725 million, with potential additional payments of up to $125 million contingent on future milestones. The acquisition, Solventum's first strategic purchase since becoming an independent company, expands its MedSurg portfolio into synthetic tissue matrices technology used in regenerative wound care, with Acera Surgical expected to generate approximately $90 million in sales in 2025. The transaction is projected to be slightly dilutive to Solventum's adjusted earnings per share in 2026 before becoming accretive in 2027.PR NewswireSolventum Completes Acquisition of Acera SurgicalSolventum has completed the acquisition of Acera Surgical, a privately held bioscience company specializing in synthetic tissue matrices for regenerative wound care. The transaction involves an upfront cash payment of $725 million plus up to $125 million in contingent payments, aiming to expand Solventum's MedSurg portfolio into acute care settings in the U.S.MassDeviceSolventum completes Acera Surgical acquisitionSolventum has completed its acquisition of Acera Surgical, a developer of soft tissue repair treatments, for up to $900 million — consisting of a $725 million cash payment plus up to $125 million in contingent payments tied to future milestones. Acera Surgical's Restrata products, which use proprietary electrospinning technology to treat complex wounds in acute care settings, generated approximately $90 million in sales in 2025. The deal is expected to be slightly dilutive to Solventum's adjusted EPS in 2026 before becoming accretive in 2027, and represents the first strategic acquisition for Solventum since its spin-off from 3M Health Care.VenturecapitalSolventum Completes Acquisition of Acera SurgicalSolventum has completed its acquisition of Acera Surgical, a bioscience company specializing in engineered materials for regenerative wound care, for an initial $725 million with potential additional payments of up to $125 million based on future milestones. The transaction is expected to be slightly dilutive to adjusted earnings per share in 2026 but accretive from 2027 onwards, with Acera projected to generate approximately $90 million in sales for 2025. The acquisition is part of Solventum's three-phased transformation plan and aims to combine Acera's innovative technology with Solventum's advanced wound care portfolio.MarketScreenerSolventum Completes Acquisition of Acera SurgicalSolventum has completed its acquisition of Acera Surgical for $725 million in upfront cash plus up to $125 million in contingent payments based on future milestones. Acera is a privately held bioscience company focused on developing fully engineered synthetic tissue matrices for regenerative wound care in acute care settings. The transaction is expected to be slightly dilutive to adjusted EPS in 2026 but accretive beginning in 2027, with Acera projected to generate approximately $90 million in sales in 2025.